A Combined Cobalt and C-14 2-Deoxyglucose Approach to Antiepileptic Drug Assessment

References

• Blacklot J. B., Oldfield E. H., Dichiro G., Tran D., Theodore W., Wright D. C., Larson S. M. Effect of barbiturate coma on glucose utilization in normal brain versus gliomas. Journal of Neurosurgery. 1987; 67: 71–75
   PubMedGoogle Scholar
• Cooper R. M., Thurlow G. A. 2-Deoxyglucose uptake in the thalamus of awake rats after neocortical ablations. Experimental Neurology 1984; 86: 261–271
   PubMedGoogle Scholar
• Cooper R. M., Thurlow G. A., Rooney B. J. 2-Deoxyglucose uptake and histologic changes in rat thalamus after neocortical ablations. Experimental Neurology 1984; 83: 134–143
   PubMedGoogle Scholar
• Craig C. R., Chiu P., Colasanti B. K. Effects of diphenylhydantion and trimethadione on seizure activity during cobalt experimental epilepsy in the rat. Neuropharmacology 1976; 15: 485–489
   PubMedGoogle Scholar
• Craig C. R., Colasanti B. K. GABA receptors, lipids and gangliosides in cobalt epileptic focus. Basic Mechanisms of the Epilepsies, A. V. Delgado-Escueta, A. A. Ward, D. M. Woodbury, R. J. Porter. Raven Press, New York, N.Y. 1986; 379–391
   Google Scholar
• Crosby G., Crane A. M., Sokoloff L. M. Local changes in cerebral glucose utilization during keta-mine anesthesia. Anesthesiology 1982; 56: 437–443
   PubMed Web of Science ®Google Scholar
• DeVore G. R., McQueen J. K., Woodbury D. M. Ketamine hydrochloride and its effect on a chronic cobalt epileptic cortical focus. Epilepsia 1976; 17: 111–117
   PubMedGoogle Scholar
• Dow R. C., Forfar J. C., McQueen J. K. The effects of some anticonvulsant drugs on cobalt-induced epilepsy. Epilepsia 1973; 14: 203–212
   PubMedGoogle Scholar
• Frey K. A., Agranoff B. W. Barbiturate-enhanced detection of brain lesions by carbon-14-labeled 2-deoxyglucose autoradiography. Science 1983; 219: 879–881
   PubMedGoogle Scholar
• Frieder B., Karpiak S. E., Rapport M. M. Effect of antiepileptic drugs and an anticonvulsant on epileptoform activity induced by antibodies to ganglioside. Experimental Neurology 1982; 78: 644–653
   PubMedGoogle Scholar
• Hammer R. P., Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. Journal of Comparative Neurology 1983; 220: 396–404
   PubMedGoogle Scholar
• Kemp J. A., Foster A. C., Wong E. H. F. Non-competitive antagonists of excitatory amino acid receptors. Trends in Neuroscience 1987; 10: 294–298
   Web of Science ®Google Scholar
• Leander J. D., Rathbun R. C., Zimmerman D. M. Anticonvulsant effects of phencyclidine-like drugs: Relation to N-methyl-d-aspartic acid antagonism. Brain Research 1988; 454: 368–372
   PubMed Web of Science ®Google Scholar
• Leccese A. P., Marquis K. L., Mattia A., Moreton J. E. The convulsant and anticonvulsant effects of phencyclidine (PCP) and PCP analogues in the rat. Behavioral, Brain Research 1986; 19: 163–169
   PubMedGoogle Scholar
• Löscher W. Basic aspects of epilepsy. Current Opinion in Neurology & Neurosurgery 1993; 6: 223–232
   PubMedGoogle Scholar
• Macdonald R. L. Anticonvulsant drugs, ion channels and neurotransmitter receptors. Current Opinion in Neurology & Neurosurgery 1991; 4: 576–581
   Google Scholar
• Macdonald R. L., Kelly K. M. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994; 35: S41–S50, (SuppI. 4)
   PubMed Web of Science ®Google Scholar
• Macdonald R. L., McLean M. J. Anticonvulsant drugs: Mechanisms of action. Basic mechanisms of the epilepsies, A. V. Delgado-Escueta, A. A. Ward, D. M. Woodbury, R. J. Porter. Raven Press, New York, N.Y. 1986; 713–736
   Google Scholar
• Macdonald R. L., Meldrum B. S. General principles: Principles of antiepileptic drug action. Antiepileptic drugs, R. Levy, R. Mattson, B. Meldrum, J. K. Penry, F. E. Dreifuss. Raven Press, New York, N.Y. 1989; 59–83
   Google Scholar
• Nehls D. G., Kurmaji A., Park C. K., McCulloch J. Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neuroscience Letters 1988; 91: 204–210
   PubMedGoogle Scholar
• Olney J. W., Labruyere Wang G., Wozniak D. F., Price M. T., Sesma M. A. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991; 254: 1515–1518
   PubMed Web of Science ®Google Scholar
• Olson M. E., Renchko P. Azaperone-ketamine as a neuroleptic sedative and anaesthetic in rats and mice. Laboratory Animal Science 1988; 38: 299–303
   PubMedGoogle Scholar
• Prichard J. W., Ransom B. R. Phenobarbital: Mechanisms of action. Antiepileptic drugs, R. Levy, R. Mattson, B. Meldrum, J. K. Penry, F. E. Dreifuss. Raven Press, New York, N.Y. 1989; 267–282
   Google Scholar
• Rail T. W., Schleifer L. S. Drugs effective in the therapy of the epilepsies. The pharmacological basis of therapeutics, A. G. Gilman, T. W. Rail, A. S. Nies, P. Taylor. Macmillan Publishing, New York, N.Y. 1990; 436–462
   Google Scholar
• Scuvee-Moreau J., Lepot M., Brotchi J., Gerebtzoff M. A., Dresse A. Action of phenytoin, etho-suximide, and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat. Archives Internationales de Pharmacodynamie et de Therapie 1977; 230: 93–99
   Google Scholar
• Sokoloff L. M., Reivich M., Kennedy C, Desrosiers M. H., Patlack C. S., Pettigrew K. D., Sakurada O., Shinohara M. The [14CJ-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anaesthetized albino rat. Journal of Neurochemistry 1977; 28: 897–916
   PubMed Web of Science ®Google Scholar
• Theodore W. H., Bairamian D., Newmark M. E., Fishbein D., Porter R. J., DiChiro G., Deitz M., Baldwin P., Margolin R., Brooks R., Jacobs G. The effect of antiepileptic drugs on cerebral glucose metabolism. Advances in Epilepto/ogy 1989; 17: 139–141
   Google Scholar
• Trottier S., Truchet M., Laroudie C. Secondary ion microanalysis in the study of cobalt-induced epilepsy in the rat. Experimental Neurology 1982; 76: 231–245
   PubMedGoogle Scholar
• Van Ostrand G., Cooper R. M. The 14C 2-deoxyglucose autoradiographic technique provides a metabolic signature of cobalt-induced focal epileptogenesis. Epilepsia 1994; 35: 939–949
   PubMedGoogle Scholar
• Veliskova J., Velisek L., Mareš P., Rokyta R. Ketamine suppresses both bicuculline- and picrotoxin-induced generalized tonic-clonic seizures during ontogenesis. Pharmacology Biochemistry & Behavior 1990; 37: 667–674
   PubMedGoogle Scholar
• Wilder B. J. Projection phenomena and secondary epileptogenesis-mirror foci. Experimental models of epilepsy, D. P. Purpura, J. K. Penry, D. B. Tower, D. M. Woodbury, R. D. Walter. Raven Press, New York, N.Y. 1972; 85–111
   Google Scholar
• Zimmerman F. T., Burgemeister B. B. A new drug for petit mat epilepsy. Neurology 1958; 8: 769–775
   PubMed Web of Science ®Google Scholar